FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Julie Cherrington

Research Profile

Chemicals & Drugs

Living Beings

Co-author Network

Publications

TOP 3
Anne-Marie O'Farrell; Andre van Vliet; Khalid Abou Farha; Julie M Cherrington; David A Campbell; Xinqiang Li; Denise Hanway; Jianke Li; Hans-Peter Guler
Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects.
Marcus Schittenhelm; Kevin W H Yee; Jeffrey W Tyner; Laura McGreevey; Andrea Haley; Ajia Town; Diana J Griffith; Troy Bainbridge; Rita M Braziel; Anne-Marie O'Farrell; Julie M Cherrington; Michael C Heinrich
FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248).
Shem Patyna; A Douglas Laird; Dirk B Mendel; Anne-Marie O'Farrell; Chris Liang; Huiping Guan; Tomas Vojkovsky; Stefan Vasile; Xueyan Wang; Jeffrey Chen; Maren Grazzini; Cheng Y Yang; Joshua O Haznedar; Juthamas Sukbuntherng; Wei-Zhu Zhong; Julie M Cherrington; Dana Hu-Lowe
SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Julie Cherrington (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2007: Anne-Marie O'Farrell; Andre van Vliet; Khalid Abou Farha; Julie M Cherrington; David A Campbell; Xinqiang Li; Denise Hanway; Jianke Li; Hans-Peter Guler
Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects.
Clinical therapeutics 2007;29(8):1692-705.
2006: Marcus Schittenhelm; Kevin W H Yee; Jeffrey W Tyner; Laura McGreevey; Andrea Haley; Ajia Town; Diana J Griffith; Troy Bainbridge; Rita M Braziel; Anne-Marie O'Farrell; Julie M Cherrington; Michael C Heinrich
FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248).
Leukemia 2006;20(11):2008-14.
2006: Shem Patyna; A Douglas Laird; Dirk B Mendel; Anne-Marie O'Farrell; Chris Liang; Huiping Guan; Tomas Vojkovsky; Stefan Vasile; Xueyan Wang; Jeffrey Chen; Maren Grazzini; Cheng Y Yang; Joshua O Haznedar; Juthamas Sukbuntherng; Wei-Zhu Zhong; Julie M Cherrington; Dana Hu-Lowe
SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity.
Molecular cancer therapeutics 2006;5(7):1774-82.
2006: Olga Potapova; A Douglas Laird; Michelle A Nannini; Angela Barone; Guangmin Li; Katherine G Moss; Julie M Cherrington; Dirk B Mendel
Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248.
Molecular cancer therapeutics 2006;5(5):1280-9.
2005: Walter Fiedler; Hubert Serve; Hartmut Döhner; Michael Schwittay; Oliver G Ottmann; Anne-Marie O'Farrell; Carlo Bello; Randy Allred; William C Manning; Julie M Cherrington; Sharianne G Louie; Weiru Hong; Nicoletta M Brega; Giorgio Massimini; Paul Scigalla; Wolfgang E Berdel; Dieter K Hossfeld
A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease.
Blood 2005;105(3):986-93.
2004: Kevin W H Yee; Marcus Schittenhelm; Anne-Marie O'Farrell; Ajia Town; Laura McGreevey; Troy Bainbridge; Julie M Cherrington; Michael C Heinrich
Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells.
Blood 2004;104(13):4202-9.
2004: Anne-Marie O'Farrell; Helene A Yuen; Beverly D Smolich; Alison L Hannah; Sharianne G Louie; Weiru Hong; Alison T Stopeck; Lewis R Silverman; Jeffrey E Lancet; Judith E Karp; Maher Albitar; Julie M Cherrington; Francis Giles
Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia.
Leukemia research 2004;28(7):679-89.
2004: Alyssa M Morimoto; Nguyen Tan; Kristina West; Grant McArthur; Guy C Toner; William C Manning; Beverly D Smolich; Julie M Cherrington
Gene expression profiling of human colon xenograft tumors following treatment with SU11248, a multitargeted tyrosine kinase inhibitor.
Oncogene 2004;23(8):1618-26.
2004: Maurizio Zangari; Elias Anaissie; Alison T Stopeck; Alyssa Morimoto; Nguyen Tan; Jeffrey E Lancet; Maureen Cooper; Alison L Hannah; Guillermo Garcia-Manero; Stefan Faderl; Andrew Lamb; Julie M Cherrington; Maher Albitar; Francis Giles
Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(1 Pt 1):88-95.
2003: Nancy K Pryer; Leslie B Lee; Regina Zadovaskaya; Xiaoming Yu; Juthamas Sukbuntherng; Julie M Cherrington; Cheryl A London
Proof of target for SU11654: inhibition of KIT phosphorylation in canine mast cell tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(15):5729-34.
2003: Anne-Marie O'Farrell; James M Foran; Walter Fiedler; Hubert Serve; Ronald L Paquette; Maureen A Cooper; Helene A Yuen; Sharianne G Louie; Heidi Kim; Susan Nicholas; Michael C Heinrich; Wolfgang E Berdel; Carlo Bello; Mark Jacobs; Paul Scigalla; William C Manning; Stephen Kelsey; Julie M Cherrington
An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(15):5465-76.
2003: James G Christensen; Randall E Schreck; Jon Burrows; Poonam Kuruganti; Emily Chan; Phuong Le; Jeffrey Chen; Xueyan Wang; Lany Ruslim; Robert Blake; Kenneth E Lipson; John Ramphal; Steven Do; Jingrong J Cui; Julie M Cherrington; Dirk B Mendel
A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo.
Cancer research 2003;63(21):7345-55.
2003: Katherine G Moss; Guy C Toner; Julie M Cherrington; Dirk B Mendel; A Douglas Laird
Hair depigmentation is a biological readout for pharmacological inhibition of KIT in mice and humans.
The Journal of pharmacology and experimental therapeutics 2003;307(2):476-80.
2003: Tinya J Abrams; Lesley J Murray; Enrico Pesenti; Vicky Walker Holway; Tina Colombo; Leslie B Lee; Julie M Cherrington; Nancy K Pryer
Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer.
Molecular cancer therapeutics 2003;2(10):1011-21.
2003: Francis Giles; Alison T Stopeck; Lewis R Silverman; Jeffrey E Lancet; Maureen A Cooper; Alison L Hannah; Julie M Cherrington; Anne-Marie O'Farrell; Helene A Yuen; Sharianne G Louie; Weiru Hong; Jorge E Cortes; Srdan Verstovsek; Maher Albitar; Susan M O'Brien; Hagop M Kantarjian; Judith E Karp
SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes.
Blood 2003;102(3):795-801.
2003: Cheryl A London; Alison L Hannah; Regina Zadovoskaya; May B Chien; Cynthia Kollias-Baker; Mona Rosenberg; Sue Downing; Gerald Post; Joseph Boucher; Narmada Shenoy; Dirk B Mendel; Gerald McMahon; Julie M Cherrington
Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(7):2755-68.
2003: Tinya J Abrams; Leslie B Lee; Lesley J Murray; Nancy K Pryer; Julie M Cherrington
SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer.
Molecular cancer therapeutics 2003;2(5):471-8.
2003: A Douglas Laird; Guangmin Li; Katherine G Moss; Robert Blake; Martin A Broome; Julie M Cherrington; Dirk B Mendel
Src family kinase activity is required for signal tranducer and activator of transcription 3 and focal adhesion kinase phosphorylation and vascular endothelial growth factor signaling in vivo and for anchorage-dependent and -independent growth of human tumor cells.
Molecular cancer therapeutics 2003;2(5):461-9.
2003: Anne-Marie O'Farrell; Tinya J Abrams; Helene A Yuen; Theresa J Ngai; Sharianne G Louie; Kevin W H Yee; Lily M Wong; Weiru Hong; Leslie B Lee; Ajia Town; Beverly D Smolich; William C Manning; Lesley J Murray; Michael C Heinrich; Julie M Cherrington
SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo.
Blood 2003;101(9):3597-605.
2003: Francis Giles; Maureen A Cooper; Lewis Silverman; Judith E Karp; Jeffrey E Lancet; Maurizio Zangari; Paul J Shami; Khuda Dad Khan; Alison L Hannah; Julie M Cherrington; Deborah A Thomas; Guillermo Garcia-Manero; Maher Albitar; Hagop M Kantarjian; Alison T Stopeck
Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseases.
Cancer 2003;97(8):1920-8.
2003: Samuel E DePrimo; Lily M Wong; Deepak B Khatry; Susan L Nicholas; William C Manning; Beverly D Smolich; Anne-Marie O'Farrell; Julie M Cherrington
Expression profiling of blood samples from an SU5416 Phase III metastatic colorectal cancer clinical trial: a novel strategy for biomarker identification.
BMC cancer 2003;3():3.
2003: Lesley J Murray; Tinya J Abrams; Kelly R Long; Theresa J Ngai; Lisa M Olson; Weiru Hong; Paul K Keast; Jacqueline A Brassard; Anne-Marie O'Farrell; Julie M Cherrington; Nancy K Pryer
SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model.
Clinical & experimental metastasis 2003;20(8):757-66.
2003: Dirk B Mendel; A Douglas Laird; Xiaohua Xin; Sharianne G Louie; James G Christensen; Guangmin Li; Randall E Schreck; Tinya J Abrams; Theresa J Ngai; Leslie B Lee; Lesley J Murray; Jeremy Carver; Emily Chan; Katherine G Moss; Joshua O Haznedar; Juthamas Sukbuntherng; Robert Blake; Li Sun; Cho Tang; Todd Miller; Sheri Shirazian; Gerald McMahon; Julie M Cherrington
In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(1):327-37.
2003: A Douglas Laird; Julie M Cherrington
Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents.
Expert opinion on investigational drugs 2003;12(1):51-64.
2002: Kevin W H Yee; Anne-Marie O'Farrell; Beverly D Smolich; Julie M Cherrington; Gerald McMahon; Cecily L Wait; Laura McGreevey; Diana J Griffith; Michael C Heinrich
SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase.
Blood 2002;100(8):2941-9.
2002: Albert T Liao; May B Chien; Narmada Shenoy; Dirk B Mendel; Gerald McMahon; Julie M Cherrington; Cheryl A London
Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors.
Blood 2002;100(2):585-93.
2002: Qingling Zhang; Wyming Lee Pang; Hui Chen; Julie M Cherrington; Kenneth Lipson; Lida Antonian; Laura K Shawver
Application of LC/MS/MS in the quantitation of SU101 and SU0020 uptake by 3T3/PDGFr cells.
Journal of pharmaceutical and biomedical analysis 2002;28(3-4):701-9.
2002: A Douglas Laird; James G Christensen; Guangmin Li; Jeremy Carver; Kimberly Smith; Xiaohua Xin; Katherine G Moss; Sharianne G Louie; Dirk B Mendel; Julie M Cherrington
SU6668 inhibits Flk-1/KDR and PDGFRbeta in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2002;16(7):681-90.
2001: James G Christensen; Randall E Schreck; Emily Chan; Xueyan Wang; C Yang; L Liu; J Cui; Li Sun; J Wei; Julie M Cherrington; Dirk B Mendel
High levels of HER-2 expression alter the ability of epidermal growth factor receptor (EGFR) family tyrosine kinase inhibitors to inhibit EGFR phosphorylation in vivo.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(12):4230-8.
2001: Michael D Miller; Nicolas A Margot; PD Lamy; Michael D Fuller; KE Anton; Andrew S Mulato; Julie M Cherrington
Adefovir and tenofovir susceptibilities of HIV-1 after 24 to 48 weeks of adefovir dipivoxil therapy: genotypic and phenotypic analyses of study GS-96-408.
Journal of acquired immune deficiency syndromes (1999) 2001;27(5):450-8.
2001: Beverly D Smolich; Helene A Yuen; K A West; Francis Giles; Maher Albitar; Julie M Cherrington
The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts.
Blood 2001;97(5):1413-21.
2000: Dirk B Mendel; Randall E Schreck; D C West; Guangmin Li; LM Strawn; S S Tanciongco; S Vasile; Laura K Shawver; Julie M Cherrington
The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(12):4848-58.
2000: LM Strawn; Fairooz Kabbinavar; D P Schwartz; E Mann; Laura K Shawver; Dennis J Slamon; Julie M Cherrington
Effects of SU101 in combination with cytotoxic agents on the growth of subcutaneous tumor xenografts.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(7):2931-40.
2000: Dirk B Mendel; A Douglas Laird; Beverly D Smolich; Robert Blake; Congxin Liang; Alison L Hannah; R M Shaheen; L M Ellis; Steven D Weitman; Laura K Shawver; Julie M Cherrington
Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent.
Anti-cancer drug design 2000;15(1):29-41.
2000: Koen K A Van Rompay; M Miller; Marta L Marthas; Nicolas A Margot; PJ Dailey; Don R Canfield; Ross P Tarara; Julie M Cherrington; NL Aguirre; Norbert Bischofberger; Niels C Pedersen
Prophylactic and therapeutic benefits of short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) administration to newborn macaques following oral inoculation with simian immunodeficiency virus with reduced susceptibility to PMPA.
Journal of virology 2000;74(4):1767-74.
2000: Julie M Cherrington; LM Strawn; Laura K Shawver
New paradigms for the treatment of cancer: the role of anti-angiogenesis agents.
Advances in cancer research 2000;79():1-38.
1999: E Frances Bowen; Julie M Cherrington; PD Lamy; Paul D Griffiths; Margaret A Johnson; Vincent C Emery
Quantitative changes in cytomegalovirus DNAemia and genetic analysis of the UL97 and UL54 genes in AIDS patients receiving cidofovir following ganciclovir therapy.
Journal of medical virology 1999;58(4):402-7.
1999: Koen K A Van Rompay; Julie M Cherrington; Marta L Marthas; PD Lamy; PJ Dailey; Don R Canfield; Ross P Tarara; Norbert Bischofberger; Niels C Pedersen
9-[2-(Phosphonomethoxy)propyl]adenine (PMPA) therapy prolongs survival of infant macaques inoculated with simian immunodeficiency virus with reduced susceptibility to PMPA.
Antimicrobial agents and chemotherapy 1999;43(4):802-12.
1999: Koen K A Van Rompay; PJ Dailey; Ross P Tarara; Don R Canfield; NL Aguirre; Julie M Cherrington; PD Lamy; Norbert Bischofberger; Niels C Pedersen; Marta L Marthas
Early short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine treatment favorably alters the subsequent disease course in simian immunodeficiency virus-infected newborn Rhesus macaques.
Journal of virology 1999;73(4):2947-55.
1999: MA Jacobson; S Wilson; HD Stanley; CD Holtzer; Julie M Cherrington; S Safrin
Phase I study of combination therapy with intravenous cidofovir and oral ganciclovir for cytomegalovirus retinitis in patients with AIDS.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1999;28(3):528-33.
1999: Mark A Wainberg; Michael D Miller; Yudong Quan; Horacio Salomon; Andrew S Mulato; PD Lamy; Nicolas A Margot; KE Anton; Julie M Cherrington
In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA.
Antiviral therapy 1999;4(2):87-94.
1999: S Safrin; Julie M Cherrington; HS Jaffe
Cidofovir. Review of current and potential clinical uses.
Advances in experimental medicine and biology 1999;458():111-20.
1999: Michael D Miller; KE Anton; Andrew S Mulato; PD Lamy; Julie M Cherrington
Human immunodeficiency virus type 1 expressing the lamivudine-associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitro.
The Journal of infectious diseases 1999;179(1):92-100.
1998: Julie M Cherrington; Michael D Fuller; PD Lamy; Richard C Miner; Jacob P Lalezari; S Nuessle; W Lawrence Drew
In vitro antiviral susceptibilities of isolates from cytomegalovirus retinitis patients receiving first- or second-line cidofovir therapy: relationship to clinical outcome.
The Journal of infectious diseases 1998;178(6):1821-5.
1998: Tomas Cihlar; Michael D Fuller; Andrew S Mulato; Julie M Cherrington
A point mutation in the human cytomegalovirus DNA polymerase gene selected in vitro by cidofovir confers a slow replication phenotype in cell culture.
Virology 1998;248(2):382-93.
1998: Michael D Miller; PD Lamy; Michael D Fuller; Andrew S Mulato; Nicolas A Margot; Tomas Cihlar; Julie M Cherrington
Human immunodeficiency virus type 1 reverse transcriptase expressing the K70E mutation exhibits a decrease in specific activity and processivity.
Molecular pharmacology 1998;54(2):291-7.
1998: Andrew S Mulato; PD Lamy; Michael D Miller; W X Li; KE Anton; Nicholas S Hellmann; Julie M Cherrington
Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from AIDS patients after prolonged adefovir dipivoxil therapy.
Antimicrobial agents and chemotherapy 1998;42(7):1620-8.
1998: Tomas Cihlar; Michael D Fuller; Julie M Cherrington
Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments.
Journal of virology 1998;72(7):5927-36.
1997: Steven G Deeks; A Collier; Jacob P Lalezari; A Pavia; D Rodrigue; W Lawrence Drew; J Toole; HS Jaffe; Andrew S Mulato; PD Lamy; W Li; Julie M Cherrington; Nicholas S Hellmann; J Kahn
The safety and efficacy of adefovir dipivoxil, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults: a randomized, double-blind, placebo-controlled trial.
The Journal of infectious diseases 1997;176(6):1517-23.
1997: X Xiong; C Flores; Michael D Fuller; Dirk B Mendel; Andrew S Mulato; K Moon; M S Chen; Julie M Cherrington
In vitro characterization of the anti-human cytomegalovirus activity of PMEA (Adefovir).
Antiviral research 1997;36(2):131-7.
1997: Andrew S Mulato; Julie M Cherrington
Anti-HIV activity of adefovir (PMEA) and PMPA in combination with antiretroviral compounds: in vitro analyses.
Antiviral research 1997;36(2):91-7.
1997: Tomas Cihlar; Michael D Fuller; Julie M Cherrington
Expression of the catalytic subunit (UL54) and the accessory protein (UL44) of human cytomegalovirus DNA polymerase in a coupled in vitro transcription/translation system.
Protein expression and purification 1997;11(2):209-18.
1997: Irene L Smith; Julie M Cherrington; R E Jiles; Michael D Fuller; William R Freeman; Stephen A Spector
High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes.
The Journal of infectious diseases 1997;176(1):69-77.
1996: Koen K A Van Rompay; Julie M Cherrington; Marta L Marthas; C J Berardi; Andrew S Mulato; A Spinner; Ross P Tarara; Don R Canfield; S Telm; Norbert Bischofberger; Niels C Pedersen
9-[2-(Phosphonomethoxy)propyl]adenine therapy of established simian immunodeficiency virus infection in infant rhesus macaques.
Antimicrobial agents and chemotherapy 1996;40(11):2586-91.
1996: A Foli; K M Sogocio; B Anderson; Mark F Kavlick; MW Saville; Mark A Wainberg; Z Gu; Julie M Cherrington; Hiroaki Mitsuya; Robert Yarchoan
In vitro selection and molecular characterization of human immunodeficiency virus type 1 with reduced sensitivity to 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA).
Antiviral research 1996;32(2):91-8.
1996: Julie M Cherrington; Andrew S Mulato; Michael D Fuller; MS Chen
Novel mutation (K70E) in human immunodeficiency virus type 1 reverse transcriptase confers decreased susceptibility to 9-[2-(phosphonomethoxy)ethyl]adenine in vitro.
Antimicrobial agents and chemotherapy 1996;40(9):2212-6.
1996: Choung U Kim; L R McGee; S H Krawczyk; E Harwood; Y Harada; S Swaminathan; Norbert Bischofberger; MS Chen; Julie M Cherrington; S F Xiong; L Griffin; Kenneth C Cundy; A Lee; B Yu; S Gulnik; J W Erickson
New series of potent, orally bioavailable, non-peptidic cyclic sulfones as HIV-1 protease inhibitors.
Journal of medicinal chemistry 1996;39(18):3431-4.
1996: Julie M Cherrington; Michael D Fuller; Andrew S Mulato; S J Allen; S C Kunder; M A Ussery; Z Lesnikowski; Ray F Schinazi; J P Sommadossi; MS Chen
Comparative kinetic analyses of interaction of inhibitors with Rauscher murine leukemia virus and human immunodeficiency virus reverse transcriptases.
Antimicrobial agents and chemotherapy 1996;40(5):1270-3.
1996: Julie M Cherrington; Richard C Miner; M J Hitchcock; Jacob P Lalezari; W Lawrence Drew
Susceptibility of human cytomegalovirus to cidofovir is unchanged after limited in vivo exposure to various regimens of drug.
The Journal of infectious diseases 1996;173(4):987-92.
1995: Z Gu; Horacio Salomon; Julie M Cherrington; Andrew S Mulato; MS Chen; Robert Yarchoan; A Foli; K M Sogocio; Mark A Wainberg
K65R mutation of human immunodeficiency virus type 1 reverse transcriptase encodes cross-resistance to 9-(2-phosphonylmethoxyethyl)adenine.
Antimicrobial agents and chemotherapy 1995;39(8):1888-91.